Acer Therapeutics Inc
ACER
ACER was delisted on the 8th of November, 2023.
28 hedge funds and large institutions have $60.9M invested in Acer Therapeutics Inc in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 7 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
3% less funds holding
Funds holding: 29 → 28 (-1)
34% less capital invested
Capital invested by funds: $92.3M → $60.9M (-$31.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.88M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$777K |
| 3 |
Barclays
London,
United Kingdom
|
+$571K |
| 4 |
Goldman Sachs
New York
|
+$442K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$2.99M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.8M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$1.23M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$813K |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$671K |
ACER Hedge Fund Activity: Q4 2018 in Review
28 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Acer Therapeutics Inc (ACER) for Q4 2018, worth a combined $60.9M — down 34% from $92.3M a quarter earlier.
Fund positioning in ACER was balanced in Q4 2018: 7 funds opened new positions, 7 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $4.88M. The largest seller was Avoro Capital Advisors, cutting an estimated $2.99M.
- 28 institutional investors held Acer Therapeutics Inc (ACER) as of Q4 2018, down from 29 in Q3 2018.
- Funds reported $60.9M of Acer Therapeutics Inc stock for Q4 2018, down 34% quarter-over-quarter.
- 7 funds opened new Acer Therapeutics Inc positions in Q4 2018 and 7 closed out, a net change of 0 holders.
- The largest Acer Therapeutics Inc buyer in Q4 2018 was Nantahala Capital Management, an estimated $4.88M added.
- The largest Acer Therapeutics Inc seller in Q4 2018 was Avoro Capital Advisors, an estimated $2.99M sold.
Based on aggregated 13F filings for Q4 2018.